ATE339406T1 - Chinazoline verbindungen als heilmittel - Google Patents

Chinazoline verbindungen als heilmittel

Info

Publication number
ATE339406T1
ATE339406T1 AT00958907T AT00958907T ATE339406T1 AT E339406 T1 ATE339406 T1 AT E339406T1 AT 00958907 T AT00958907 T AT 00958907T AT 00958907 T AT00958907 T AT 00958907T AT E339406 T1 ATE339406 T1 AT E339406T1
Authority
AT
Austria
Prior art keywords
compounds
chinazoline
remedies
formulaand
diseases
Prior art date
Application number
AT00958907T
Other languages
English (en)
Inventor
Robert Toms Jacobs
James Folmer
Thomas Richard Simpson
Bipinchandra Chaudhari
William Jackson Frazee
Timothy Wayne Davenport
Gajendran Sundarababu
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE339406T1 publication Critical patent/ATE339406T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00958907T 1999-09-23 2000-09-18 Chinazoline verbindungen als heilmittel ATE339406T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15562399P 1999-09-23 1999-09-23

Publications (1)

Publication Number Publication Date
ATE339406T1 true ATE339406T1 (de) 2006-10-15

Family

ID=22556162

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00958907T ATE339406T1 (de) 1999-09-23 2000-09-18 Chinazoline verbindungen als heilmittel

Country Status (8)

Country Link
US (1) US6399603B1 (de)
EP (1) EP1218358B1 (de)
JP (1) JP2003509501A (de)
AT (1) ATE339406T1 (de)
AU (1) AU7031500A (de)
DE (1) DE60030741T2 (de)
ES (1) ES2270867T3 (de)
WO (1) WO2001021598A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1088821A1 (de) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmazeutisch wirksamer Sulfonamid Derivate
EP1257536A1 (de) * 2000-01-27 2002-11-20 Cytovia, Inc. Substituierte nicotinamiden und analoge als caspaseaktivatoren und apoptose-induzierende mittel und ihre verwendung
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
MXPA03002788A (es) * 2000-09-29 2004-12-13 Neurogen Corp Moduladores de receptor c5a de molecula pequena de alta afinidad.
US20040198650A1 (en) * 2001-03-29 2004-10-07 Poul Jensen Means for inhibiting proteolytical processing of parkin
AT413485B (de) * 2001-04-09 2006-03-15 Hemoteq Gmbh Mit einem pharmazeutikum beschichteter stent
EP1382335A4 (de) 2001-04-26 2006-05-24 Nippon Shinyaku Co Ltd Medikamente
CA2461603A1 (en) * 2001-09-24 2003-04-03 Elan Pharmaceuticals, Inc. Substituted amines for the treatment of neurological disorders
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
IL164302A0 (en) * 2002-03-29 2005-12-18 Chiron Corp Substituted benzazoles and use thereof as raf kinase inhibitors
US8299108B2 (en) * 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
EP1398032A1 (de) * 2002-09-10 2004-03-17 PheneX Pharmaceuticals AG 4-Oxochinazoline, die an den LXR Kernrezeptor binden
CA2520124A1 (en) * 2003-03-28 2004-10-14 Chiron Corporation Use of benzazole compounds for immunopotentiation
EP1646615B1 (de) 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
JP2007501804A (ja) * 2003-08-08 2007-02-01 バーテックス　ファーマシューティカルズ　インコーポレイテッド 電位開口型のナトリウムチャネルのインヒビターとして有用な組成物
WO2005030131A2 (en) * 2003-09-23 2005-04-07 Replidyne, Inc Bis-quinazoline compounds for the treatment of bacterial infections
KR20060118472A (ko) * 2003-10-16 2006-11-23 카이론 코포레이션 치환 벤자졸 및 ｒａｆ 키나아제의 저해제로서 그것의 사용
WO2006082001A1 (en) 2005-02-07 2006-08-10 F.Hoffmann-La Roche Ag Heterocyclic substituted phenyl methanones as inhibitors of the glycine transporter 1
AU2007231594A1 (en) 2006-03-23 2007-10-04 Amgen Inc. 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases
US20110053932A1 (en) * 2007-06-21 2011-03-03 Irm Llc Protein Kinase Inhibitors and Methods for Using Thereof
EP2226315A4 (de) 2007-12-28 2012-01-25 Carna Biosciences Inc 2-aminochinazolin-derivat
JP5370957B2 (ja) 2008-08-20 2013-12-18 学校法人日本大学 アポトーシス抑制剤
WO2010045374A1 (en) * 2008-10-15 2010-04-22 Gilead Palo Alto, Inc. 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
AU2010286691A1 (en) 2009-08-26 2012-04-19 Cylene Pharmaceuticals, Inc. Condensed quinolines as protein kinase modulators
US9051296B2 (en) 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
CN101919833B (zh) * 2010-07-16 2012-01-11 暨南大学 一种芳香类化合物作为制备Caspase 3抑制剂的用途
JP6159814B2 (ja) * 2012-11-09 2017-07-05 コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ Ｍａｌｔ１の低分子阻害剤
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
PH12019500143B1 (en) * 2013-08-23 2023-03-24 Neupharma Inc Certain chemical entities, compositions, and methods
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
EP3237397B1 (de) 2014-12-24 2018-11-21 Gilead Sciences, Inc. Isochinolinverbindungen zur behandlung von hiv
ES2735087T3 (es) * 2014-12-24 2019-12-16 Gilead Sciences Inc Compuestos de pirimidina fusionados para el tratamiento de VIH
TWI699355B (zh) * 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
AU2016220219B2 (en) 2015-02-17 2020-05-14 Neupharma, Inc. Certain chemical entities, compositions, and methods
MX383376B (es) 2015-03-24 2025-03-13 Shanghai Yingli Pharm Co Ltd Derivado de un anillo condensado y método de preparación, compuesto intermedio, composición farmacéutica y uso del mismo.
JP6966423B2 (ja) 2015-04-24 2021-11-17 グアンジョウ マキシノベル ファーマシューティカルズ カンパニー リミテッド 縮合環ピリミジンアミノ誘導体、その製造方法、中間体、薬学的組成物及び応用
KR102591886B1 (ko) * 2015-07-21 2023-10-20 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. 축합고리 피리미딘계 화합물, 중간체, 이의 제조 방법, 조성물 및 응용
DK3390364T3 (da) 2015-12-17 2020-10-12 Biokine Therapeutics Ltd Små molekyler til hæmning af kemokinaktivitet og/eller cancercellevækst
EP3390378B1 (de) 2015-12-17 2022-03-30 AlonBio Ltd. Kleine moleküle gegen krebs
CA3033370A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
US10973829B2 (en) 2016-09-19 2021-04-13 Novartis Ag Therapeutic uses of a C-RAF inhibitor
IL311471A (en) 2017-05-02 2024-05-01 Novartis Ag Combination therapy
EP4563150A3 (de) 2019-05-13 2025-07-23 Novartis AG Neue kristalline formen von n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonikotinamid als raf-hemmer zur behandlung von krebs
AU2020276793A1 (en) 2019-05-15 2022-01-20 Alonbio Ltd. Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death
CN113354660B (zh) * 2020-03-06 2024-04-23 广州再极医药科技有限公司 噻吩并嘧啶类衍生物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2488379A (en) * 1949-11-15 Quinazoline derivatives
GB585363A (en) * 1944-08-31 1947-02-05 Erancis Henry Swinden Curd New heterocyclic compounds
US4079057A (en) * 1977-05-31 1978-03-14 Bristol-Myers Company Selective immunosuppressive agents
DD225131A1 (de) * 1984-01-30 1985-07-24 Akad Wissenschaften Ddr Verfahren zur herstellung 2-substituierter 3,4-dihydrochinazolin-4-one
TW334434B (en) * 1995-05-16 1998-06-21 Kanebo Ltd Novel quinazoline compound and anti-tumor agent
AU5648599A (en) * 1998-09-11 2000-04-03 Kyorin Pharmaceutical Co. Ltd. Phosphonic ester derivatives and process for producing the same
WO2000015604A1 (fr) * 1998-09-11 2000-03-23 Kyorin Pharmaceutical Co., Ltd. Derives de diesters maloniques et leur procede d'obtention

Also Published As

Publication number Publication date
US6399603B1 (en) 2002-06-04
JP2003509501A (ja) 2003-03-11
ES2270867T3 (es) 2007-04-16
EP1218358B1 (de) 2006-09-13
DE60030741D1 (de) 2006-10-26
WO2001021598A1 (en) 2001-03-29
EP1218358A1 (de) 2002-07-03
DE60030741T2 (de) 2007-09-06
AU7031500A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
DE69931930D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
DK1200412T3 (da) Antiproliferative imidazolforbindelser
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
ATE355288T1 (de) Verbindungen und therapeutische methoden
BR9711986A (pt) Compostos farmac-uticos
DE60105025D1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
NO20020282D0 (no) Nytt difenylpiperidinderivat
DE69729183T2 (de) Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
GB9907571D0 (en) Compounds
SE0003476D0 (sv) Compounds
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
SE0004827D0 (sv) Therapeutic compounds
DE69626544T2 (de) Arzneistoffe
DE60114597D1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
NO20014889D0 (no) Fremgangsmåte for fremstilling av medisinske midler
PT1551850E (pt) 2 oxo-voruscharina e seus derivados
ITTO20001109A0 (it) Composizione farmaceutica per il trattamento anti m. ulcerans.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties